Showing results (1391-1400 of 4,519) with videos related to

Sort By:
Pageof 452
Future Oncology (London, England)|February 17, 2022
PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USAJohannes Uhlig, Stacey Stein, Hyun S Kim
Future Oncology (London, England)|February 11, 2022
Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid TumorBorys Hrinczenko, Nicholas Iannotti, Sanjay Goel, et al.
Future Oncology (London, England)|November 2, 2021
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium databaseEmre Yekedüz, İsmail Ertürk, Deniz Tural, et al.
Future Oncology (London, England)|January 27, 2022
Real-world outcomes with second-line therapy in advanced esophageal squamous cell carcinoma using SEER-Medicare dataMark Danese, Joseph Gricar, Pranav Abraham
Future Oncology (London, England)|January 27, 2022
Discovering the first US FDA-approved computer-aided polyp detection systemMarco Spadaccini, Alessandro De Marco, Gianluca Franchellucci, et al.
Future Oncology (London, England)|January 27, 2022
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocolNajib Ben Khaled, Max Seidensticker, Jens Ricke, et al.
Future Oncology (London, England)|March 15, 2022
Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantationAmirhossein Azhie, Robert C Grant, Michael Herman, et al.
Future Oncology (London, England)|March 21, 2022
Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancerLei Zhang, Yijiao Qian, Jinnan Li, et al.
Future Oncology (London, England)|April 7, 2022
Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterationsAndrea Franza, Marta Pirovano, Patrizia Giannatempo, et al.
Future Oncology (London, England)|April 11, 2022
Plain language summary of publication: new information for the potential role of afatinib in treating people with NRG1 gene fusion-positive cancerJacques Cadranel
Pageof 452